The role of clinical pharmacist on lipid control in dyslipidemic patients in North of Jordan

International Journal of Clinical Pharmacy

Volumn 33, Issue 2, 2011, Pages 229-236

  Tahaineh, Linda ^a   Albsoul Younes, Abla ^b   Al Ashqar, Eman ^a   Habeb, Ala ^a  

^a JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

^b UNIVERSITY OF JORDAN   (Jordan)

Author keywords

Clinical; Collaboration; Dyslipidemia; Jordan; Lipid clinic; Pharmacist; Physicians

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; FLUINDOSTATIN; GEMFIBROZIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PHARMACY; CONTROLLED STUDY; COOPERATION; DISEASE CONTROL; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTRANSAMINASEMIA; JORDAN; LIFESTYLE MODIFICATION; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; CHI-SQUARE DISTRIBUTION; COOPERATIVE BEHAVIOR; DYSLIPIDEMIAS; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPOLIPIDEMIC AGENTS; INTERDISCIPLINARY COMMUNICATION; JORDAN; LIPIDS; MALE; MIDDLE AGED; PATIENT CARE TEAM; PHARMACISTS; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; PROFESSIONAL ROLE; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 79960161372     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-011-9479-0     Document Type: Article

References (19)

1. Haung PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2006;2(5-6):231-7.
2. Hammoudeh AJ, Izraiq M, Al-Mousa E, Al-Tarawneh H, Elharassis A, Mahadeen Z, et al. Serum lipid profiles with and without CAD: Jordan hyperlipidaemia and related targets study (JoHARTS-1). East Mediterr Health J. 2008;14(1):24-32. (Pubitemid 351753089)
3. Geller JC, Cassens S, Brosz M, Keil U, Bernarding J, Kropf S, et al. Achievement of guideline-defined treatment goals in primary care: the German coronary risk management (CoRiMa) study. Eur Heart J. 2007;28:3051-8. (Pubitemid 350262271)
4. Bozovich M, Rubino CM, Edmunds J. Effect of a clinical pharmacistmanaged lipid clinic on achieving national cholesterol education program low density lipoprotein goals. Pharmacotherapy. 2000;20(11):1375-83.
5. Carter BL, Malone DC, Billups SJ, Valuck RJ, Barnette DJ, Sintek CD, et al. Interpreting the findings of the IMPROVE study. Am J Health Sys Pharm. 2001;58(14):1330-7. (Pubitemid 32656225)
6. Yates S, Annis L, Pippins J, Walden S. Does a lipid clinic increase compliance with cholesterol education program treatment guidelines? Report of a case-matched controlled study. South Med J. 2001;94:907-9. (Pubitemid 33641760)
7. Mazzolini TA, Irons BK, Schell EC, Seifert CF. Lipid levels and use of lipid-lowering drugs for patients in pharmacist-managed lipid clinics versus usual care in a 2 VA medical centers. J Manag Care Pharm. 2005;11(9):763-71.
8. Till LT Jr, Voris JC, Horst JB. Assessment of clinical pharmacist management of lipid-lowering therapy in a primary care setting. J Manag Care Pharm. 2003;9(3):269-73.
9. Lee VWY, Fan CSY, Li AWM, Chau ACY. Clinical impact of a pharmacist co-managed programme on hyperlipidaemia management in Hong Kong. J Clinic Pharm Therap. 2009;34:407-14.
10. Phumipamorn S, Pongwecharak J, Soorapan S, Pattharachayakul S. Effects of the pharmacist's input on glycaemic control and cardiovascular risks in Muslims diabetes. Prim Care Diabetes. 2008;2(1):31-7. Abstract.
11. Al-Wazaify M, Albsoul-Younes A. Pharmacy in Jordan. Am J of Health Sys Pharm. 2005;62(23):2548-51. (Pubitemid 41720576)
12. McDonough RP, Doucette WR. Developing collaborative working relationships between pharmacists and physicians. J Am Pharm Assoc. 2001;41(5):682-92.
13. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285: 2486-97.
14. Tahaineh LM, Wazaify M, Albsoul-Younes A, Khader Y, Zaidan M. Perceptions, experiences, and expectations of physicians in hospital settings in Jordan regarding the role of the pharmacist. Res Social Adm Pharm. 2009;5(1):63-70.
15. Ali F, Laurin M-Y, Lariviere C, Tremblay D, Cloutier D. The effect of pharmacist intervention and patient education on lipidlowering medication compliance and plasma cholesterol levels. Can J Clin Pharmacol. 2003;10:101-6. (Pubitemid 37254374)
16. Bogden PE, Koontz LM, Williamson P, Abbott RD. The physician and pharmacist team. An effective approach to cholesterol reduction. J Gen Intern Med. 1997;12:158-64. (Pubitemid 27180568)
17. Chiu CC, Wu SS, Lee PY, Huang YC, Tan TY, Chang KC. Control of modifiable risk factors in ischemic stroke outpatients by pharmacist intervention: an equal allocation stratified randomized study. J Clinic Pharm Therap. 2008;33:529-35.
18. Davidson MH, Ose L, Frohlich J, Scott RS, Dujovne CA, Escobar ID, et al. Differential effects of simvastatin and atorvastatin on high density lipoprotein cholesterol and apolipoprotein A-1 are consistent across hypercholesterolemic patient subgroups. Clin Cardiol. 2003;26:509-14. (Pubitemid 37346086)
19. Bevilacqua M, Guazzini B, Righini V, Barella M, Toscano R, Chebat E. Metabolic effects of fluvastatin extended release 80 mg and atorvastatin 20 mg in patients with type 2 diabetes mellitus and low serum high-density lipoprotein cholesterol levels: a 4-month, prospective, open label, randomized, blinded-end point (Probe) trial. Curr Ther Res. 2004;65(4):330-44. (Pubitemid 39361163)